| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/19/2004 | US20040033986 Anti tubercular drug: compositions and methods |
| 02/19/2004 | US20040033985 Composition for regulating animal growth, method of manufacture and use thereof |
| 02/19/2004 | US20040033983 Dietetic mixtures comprising polyglucomannans, excipients and lipase inhibitors such as orlistat |
| 02/19/2004 | US20040033982 Viral inhibition by n-docosanol |
| 02/19/2004 | US20040033981 Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis |
| 02/19/2004 | US20040033980 Method of down-regulating gene expression |
| 02/19/2004 | US20040033978 Antisense oligonucleotides complementary to and that hybridize with RNA, used for gene expression inhibition, prophylaxis and medical diagnosis |
| 02/19/2004 | US20040033972 Treatment of mycobacterium tuberculosis with antisense polynucleotides |
| 02/19/2004 | US20040033970 For treatment of bacterial infections |
| 02/19/2004 | US20040033966 Method for preparing dexchlor tannate |
| 02/19/2004 | US20040033965 Method for treating obesity |
| 02/19/2004 | US20040033964 For treating atheroma, tumors and other neoplastic tissue; treating atherosclerotic inflammation |
| 02/19/2004 | US20040033963 Urea composition |
| 02/19/2004 | US20040033961 Comprises pseudoephedrine-/dexchlorpheniramine-/ dextromethorphan- tannates; for treating coryza associated with sinusitis, allergic rhinitis, and common cold; antihistaminic/decongestant/antitussive agents |
| 02/19/2004 | US20040033960 Ophthalmic irrigating solution adapted for use in lasik surgery |
| 02/19/2004 | US20040033959 Improved bioavailability |
| 02/19/2004 | US20040033945 Pharmaceutical compositions for treating asthenia or anaemia or for making a food supplement |
| 02/19/2004 | US20040033941 For suppressing acute chronic rejection responses of a transplant recipient |
| 02/19/2004 | US20040033938 Cyclooxygenase-2 inhibitor and antibacterial agent combination for intramammary treatment of mastitis |
| 02/19/2004 | US20040033936 Reduced or "leuco" forms produced and/or stabilised by mixing the unreduced compounds or the reduced compounds, respectively, with acid and a sulphydryl compound, especially a sulphur-containing amino acid, or peptide or derivative |
| 02/19/2004 | US20040033935 Novel imidazole derivatives, production method thereof and use thereof |
| 02/19/2004 | US20040033934 Antimalarial and antiproliferative pharmacophore models, novel tryptanthrin compounds having increased solubility, and methods of making and using thereof |
| 02/19/2004 | US20040033933 Process for preparing composition comprising medicinal herb extract for preventing and curing arthritis and composition thereof |
| 02/19/2004 | US20040033916 Disinfecting composition |
| 02/19/2004 | US20040033602 Using small interfering RNA (siRNA) sequences and polypeptides containing enzymatic domains to control gene expression in cell systems; antisense agents |
| 02/19/2004 | US20040033550 Method of isolating biologically active fraction containing clinically acceptable native S-lipopolysaccharides obtained from bacteria producing endotoxic lipopolysaccharides |
| 02/19/2004 | US20040033548 Compositions and methods for regulating bacterial pathogenesis |
| 02/19/2004 | US20040033535 Antibodies to OPGL |
| 02/19/2004 | US20040033524 Using presence of restriction fragment length polymorphisms in adrenergic receptors to diagnosis hypertension, eating and cardiovascular disorders and identify individual who may benefit from adrenergic blocking agents |
| 02/19/2004 | US20040033520 Diagnosing metastatic colorectal, stomach and/or esophageal cancer in vitro; immunoassay; radioimaging tumors; immunotherapeutics; genetic vaccines |
| 02/19/2004 | US20040033502 Diagnosing cancer of the alimentary canal using differentail expression patterns of tumor marker proteins such as apolipoprotein C-1, galectin 4, keratin 18, annexin A10 and cathepsin E |
| 02/19/2004 | US20040033491 Proteins and nucleic acids encoding same |
| 02/19/2004 | US20040033487 Comprises nucleotide sequences coding associated with glycosylation of viral structural polypeptides; prototype immunogens for treatment and prevention of viral disease; genetic vaccines |
| 02/19/2004 | US20040033480 Use of resveratrol to regulate expression of apolipoprotein A1 |
| 02/19/2004 | US20040033280 Extraction of pharmaceutically active components from plant materials |
| 02/19/2004 | US20040033277 Lipid soluble extract of rhizomes and leaves of Curcuma species of Zingiberaceae family |
| 02/19/2004 | US20040033271 Methods for contemporaneous administration of levamisole and 5-fluorouracil |
| 02/19/2004 | US20040033269 Critical fluid antimicrobial compositions and their use and generation |
| 02/19/2004 | US20040033267 Nanoparticulate compositions of angiogenesis inhibitors |
| 02/19/2004 | US20040033263 Reduced formate poly(alkylene oxides) with secondary amines for reducing impurity formation |
| 02/19/2004 | US20040033262 Sustained release pharmaceutical composition of a cephalosporin antibiotic |
| 02/19/2004 | US20040033260 Comprise both chelated and unchelated zinc ions, wherein the quantity of chelated zinc ions is at least 50% |
| 02/19/2004 | US20040033259 Particularly levothyroxine sodium; unit dosage form containing an alditol, a saccharide, and optionally further excipients |
| 02/19/2004 | US20040033257 Pharmaceutical formulation in a drug delivery system and process for preparing the same |
| 02/19/2004 | US20040033255 For preventing, inhibiting, and/or diminishing the intentional and/ or inadvertent misuse or abuse of a transdermal delivery device |
| 02/19/2004 | US20040033254 Transdermal drug delivery system with improved water absorbability and adhesion properties |
| 02/19/2004 | US20040033253 Transdermal-delivery device |
| 02/19/2004 | US20040033252 Containing a branched-chain amino acid such as valine, leucine or isoleucine, or 2-aminonorbornane-2-carboxylic acid |
| 02/19/2004 | US20040033250 Implantable polymeric device for sustained release of buprenorphine |
| 02/19/2004 | US20040033247 Composition in the form of an emulsion that can be used to treat plantar bromhidrosis and/or hyperhidrosis |
| 02/19/2004 | US20040033246 L-histidine: and one or more of comfrey extract, yeast extract and ceramide. |
| 02/19/2004 | US20040033229 PSMA antibodies and protein multimers |
| 02/19/2004 | US20040033223 Curative and preventive activity in the pathogenesis of thrombo-embolic and haemostatic diseases of arterial or venous origin |
| 02/19/2004 | US20040033222 Anticoagulant and fibrinolytic therapy uning p38 MAP kinase inhibitors |
| 02/19/2004 | US20040033210 Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with prostaglandin inhibitor |
| 02/19/2004 | US20040033207 Cleansers of soaps, surfactants, detergents, and mixtures, and a soybean derived natural epidermal growth factor receptor inhibitor (egfr) |
| 02/19/2004 | US20040033202 Nanoparticulate sterol formulations and novel sterol combinations |
| 02/19/2004 | US20040033201 Aerosol container has a non-metal interior surface which has been found to reduce chemical degradation of such steroids |
| 02/19/2004 | US20040033198 Methods for determining effects of maternal treatments on offspring |
| 02/19/2004 | DE19930030B4 CO-3-ungesättigte Fettsäuren enthaltende orale Darreichungsform CO-3 unsaturated fatty acids containing oral dosage form |
| 02/19/2004 | DE19860373B4 Mundpflegemittel und Verwendung von sphärischen Mikropartikeln The oral care composition and use of spherical microparticles |
| 02/19/2004 | DE10248412A1 Rapidly acting, easily administered suppositories for treatment and/or prophylaxis of hypoglycemia, preferably comprising monosaccharide (source) as active agent |
| 02/19/2004 | DE10237423A1 Treating immunological (or related) diseases, e.g. inflammatory bowel disease, rheumatoid arthritis or psoriasis, comprises administration of 3-methylene-2-indolinone derivative or quinazoline compound |
| 02/19/2004 | DE10237379A1 Production of formic acid-formate e.g. preservative and animal feed additive, comprises partial hydrolysis of methyl formate, separation of formic acid, base hydrolysis of remaining ester and combination with formic acid |
| 02/19/2004 | DE10237085A1 Treatment or prevention of parasitic helminth infections, especially filariasis, in humans or animals, using oxyamino-substituted phosphonic or phosphinic acid compounds |
| 02/19/2004 | DE10236610A1 Antimicrobial composition, e.g. useful against acne and body odors, comprises hydroxydiphenyl ethers combined with mono- or oligo-glycerol monocarboxylic acid monoesters, glyceryl ethers or methylphenylbutanol |
| 02/19/2004 | DE10236405A1 New 4-(3-oxo-estra-4,9-dien-11 beta-yl)-benzaldehyde oximes, are progesterone receptor modulators useful in female contraception, hormone replacement therapy and treatment of gynecological disorders |
| 02/19/2004 | DE10236340A1 New heteroar(alkan)oyl-substituted phenyl-beta-alaninamide derivatives, useful as broad-spectrum antibacterial agents in human or veterinary medicine |
| 02/19/2004 | DE10235639A1 New prodrugs of benzimidazole-5-carboxamide derivative thrombin inhibitor, useful for treating or preventing thrombotic diseases, are well tolerated on subcutaneous injection |
| 02/19/2004 | DE10235556A1 Medicament for treating substance cravings, especially alcohol and/or tobacco abuse, comprising separate dosage forms for continuous release of nicotinic receptor modulator and rapid delivery of galanthamine |
| 02/19/2004 | DE10235475A1 Composition in the form of pellets containing benzimidazole useful for treating gastric disorders comprises an inert core to which a layer containing benzimidazole with microcrystalline cellulose is applied and outer layer |
| 02/19/2004 | DE10234673A1 Heißschmelz-TTS zur Verabreichung von Rotigotin Hot melt TTS for the administration of rotigotine |
| 02/19/2004 | DE10233500A1 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel and its use as a medicament |
| 02/19/2004 | DE10217555A1 Physiologisch verträgliche, Phospholipid-haltige, stabile und harte Matrix Physiologically acceptable, phospholipid-containing, stable and hard matrix |
| 02/19/2004 | CA2840721A1 Method of preparing modafinil polymorphic form i |
| 02/19/2004 | CA2804385A1 Method of preparing modafinil polymorphic form i |
| 02/19/2004 | CA2746788A1 Modafinil polymorphic forms |
| 02/19/2004 | CA2497658A1 Chromone derivatives as matrix metalloproteinase inhibitors |
| 02/19/2004 | CA2495684A1 Use of n-acetyl-d-glucosamine in the manufacture of a medicament for treating urogenital tract infection |
| 02/19/2004 | CA2495659A1 Process for hydroxyazapirones |
| 02/19/2004 | CA2495518A1 Bicyclic heteroaromatic compounds as kinase inhibitors |
| 02/19/2004 | CA2495516A1 Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia |
| 02/19/2004 | CA2495502A1 Methods for treating carbonic anhydrase mediated disorders |
| 02/19/2004 | CA2495498A1 Use of cgrp antagonist compounds for treatment of psoriasis |
| 02/19/2004 | CA2495493A1 Cereal based food product comprising dha and/or epa |
| 02/19/2004 | CA2495489A1 Combination of vegf receptor tyrosine kinase inhibitors for treatment of cancer |
| 02/19/2004 | CA2495487A1 Combination of zd6474, an inhibitor of the vascular endothelial growth factor receptor, with radiotherapy in the treatment of cancer |
| 02/19/2004 | CA2495418A1 Medicament and method for reducing alcohol and/or tobacco consumption |
| 02/19/2004 | CA2495266A1 Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases |
| 02/19/2004 | CA2495245A1 Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases |
| 02/19/2004 | CA2495216A1 3-pyrrolyl-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors |
| 02/19/2004 | CA2495116A1 Antimicrobial charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and method of use thereof |
| 02/19/2004 | CA2495108A1 Therapeutic use of aryl amino acid derivatives |
| 02/19/2004 | CA2495103A1 Pharmaceutical compositions comprising fk506 derivatives and their use for the treatment of allergic diseases |
| 02/19/2004 | CA2495085A1 Diagnosis and treatment of tuberous sclerosis |
| 02/19/2004 | CA2495071A1 Isosorbide mononitrate compositions and methods of their use |
| 02/19/2004 | CA2495067A1 Mcp-1 receptor antagonists and method of use thereof |
| 02/19/2004 | CA2494944A1 A method for monitoring the effectiveness of tetracycline in the treatment of asthma |
| 02/19/2004 | CA2494942A1 Substituted benzimidazole compounds |
| 02/19/2004 | CA2494930A1 Modified forms of interfering rna molecules |